ATCC provides a large collection of fully characterized and authenticated cell lines, human primary cells, and advanced cell models such as checkpoint luciferase reporter cells and CAR-T target luciferase reporter cells that support immuno-oncology therapeutic development.

This guide organizes our ATCC tumor cell lines according to gene of interest and provides information for each line about the specific mutation.

A comprehensive guide providing details and data on our AKT, BRAF, EGFR, ERK, FGFR, MET, MYC, PI3K, PTEN, and RAS genetic alteration cell panels.

With genome editing tools such as CRISPR/Cas9, ATCC has created isogenic cell lines with mutants of key oncogenes, which are ideal for identifying novel, personalized treatment regimens. Explore our resources.

The value of tumor cell lines, as research models and drug discovery tools, is greatly enhanced when there is an understanding of the underlying genetic abnormalities that drive their phenotype. ATCC has taken the first step for your research by annotating our tumor cell lines with gene mutation data from the Sanger Institute COSMIC database, and additional in-house testing.

Tumor-derived cell lines matched to either normal or metastatic cell lines obtained from the same patient provide a valuable resource for cancer studies.